NEW YORK — U.S.-traded shares of Canadian drug developer Aeterna Zentaris Inc. jumped Monday as a Rodman & Renshaw analyst reaffirmed a positive outlook for the company, citing its product pipeline.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The stock rose 25 cents, or 15 percent, to $1.93 in afternoon trading amid a rally in the broader market. Shares have traded between 75 cents and $3.25 over the last 52 weeks.
Rodman & Renshaw analyst Reni Benjamin reaffirmed a "Market Outperform" rating and $3 share price target in a note to investors. He cited positive developments within the company's pipeline, which include a mix of potential cancer and endocrinology drugs.
The company's drug candidate perifosine is currently in late-stage development as a potential multiple myeloma treatment with partner Keryx Biopharmaceuticals Inc. It is also being studied as a potential colon cancer treatment.
In April, the Europe Medicines Agency indicated an ongoing study is sufficient to provide the data needed for a marketing application on the drug, in combination with the cancer treatment Velcade. Also in April, the U.S. Food and Drug Administration gave perifosine a "fast track" designation as a potential colon cancer drug, which allows for a faster review of a potential treatment intended for a serious or life-threatening disease.
Benjamin also said the company has a promising range of early- and midstage programs, including AEZS-108 for various types of tumors.
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.